Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biotechs Need To Work Harder To Grab What Capital Remains, E&Y Reports

Executive Summary

Biotechs fared better than expected in 2009, but the market still is not healthy. In the U.S., 20 percent of companies raised 78.5 percent of the capital, widening the already vast gap between the "have" and "have nots," Ernst & Young notes in its annual Beyond Borders report

You may also be interested in...

Biotechs Need To Be More Differentiated To Succeed, E&Y Reports

The 25th annual Ernst & Young report shows that biotechs have fewer exit strategies than ever and that pre-clinical stage companies still have a hard time finding financing.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts